Key Insights

Highlights

Success Rate

79% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

7.8%

4 terminated out of 51 trials

Success Rate

78.9%

-7.6% vs benchmark

Late-Stage Pipeline

12%

6 trials in Phase 3/4

Results Transparency

13%

2 of 15 completed with results

Key Signals

2 with results79% success

Data Visualizations

Phase Distribution

43Total
Not Applicable (10)
Early P 1 (1)
P 1 (7)
P 2 (19)
P 3 (6)

Trial Status

Unknown18
Completed15
Recruiting12
Terminated4
Active Not Recruiting1
Not Yet Recruiting1

Trial Success Rate

78.9%

Benchmark: 86.5%

Based on 15 completed trials

Clinical Trials (51)

Showing 20 of 20 trials
NCT07739121Recruiting

Benchmarking Large Language Models Against Tumour Boards for Oncology Treatment Recommendations

NCT07222800Phase 3Recruiting

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

NCT04962958Phase 2Completed

Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery

NCT03303495Phase 3Recruiting

A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC

NCT06794073Not ApplicableRecruiting

Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study

NCT03221335Not ApplicableRecruitingPrimary

EUS-guided RFA for Solid Abdominal Neoplasms

NCT04556344Not ApplicableCompletedPrimary

Effectiveness of an Educational Intervention Aimed at Increasing the Emotional Competencies of Patients Under Surveillance After Antineoplastic Treatment of Oesogastric or Bronchopulmonary Cancer

NCT07196540Phase 2Not Yet RecruitingPrimary

IP rmhTNF-NC + Tislelizumab + Palliat RT for GIT Tumor Malignant Ascites After Failed Std Tx

NCT04518852Phase 2Completed

TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC

NCT01832116Phase 1Completed

89Zr-MMOT PET Imaging in Pancreatic and Ovarian Cancer Patients

NCT06365866Not ApplicableRecruiting

Evaluate the Efficacy of Adding Intraluminal Brachytherapy After CCRT for Local-regional Thoracic Esophageal Cancer.

NCT05624099Phase 2Recruiting

Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.

NCT05602935Phase 2Active Not Recruiting

Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study

NCT06026800Phase 1RecruitingPrimary

Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Combination With Standard First-line Treatment in Subjects With Advanced Digestive System Neoplasms

NCT06026774Phase 1RecruitingPrimary

Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Subjects With Resected Digestive System Neoplasms

NCT06019702Phase 1RecruitingPrimary

Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen Alone in Subjects With Advanced Digestive System Neoplasms

NCT04644315Phase 2Terminated

A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors

NCT01964430Phase 3Completed

Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)

NCT05913661Phase 2Unknown

Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

NCT03717298Phase 2Completed

Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma

Scroll to load more

Research Network

Activity Timeline